ASCO 2019 | SurVaxM: A vaccine combined with chemo/radiotherapy for glioblastoma

Speaking from the American Society of Hematology (ASCO) 2019 Annual Meeting, held in Chicago, IL, Manmeet Singh Ahluwalia, MD, FACP, of the Cleveland Clinic, Cleveland, OH, discusses an update of the clinical phase II trial of the survivin based vaccine, SurVaxM. Here, Dr Ahluwalia explains how, when used in combination with chemotherapy and radiotherapy to treat newly diagnosed glioblastoma multiforme (GBM), SurVaxM is shown to increase overall survival from the day of SurVaxM administration in both patients with MGMT-Unmethylated GBM and MGMT-Methylated GBM.